{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Myeloid+Leukemia+%28AML%29&page=19", "query": { "condition": "Acute Myeloid Leukemia (AML)", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 2378, "total_pages": 238, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Myeloid+Leukemia+%28AML%29&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Myeloid+Leukemia+%28AML%29&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T05:54:29.485Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04402541", "title": "Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia, in Relapse", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "CB-5339", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cleave Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2020-06-08", "completion_date": "2023-07-23", "has_results": false, "last_update_posted_date": "2023-08-31", "last_synced_at": "2026-10-15T05:54:29.485Z", "location_count": 7, "location_summary": "Los Angeles, California • Fairway, Kansas • New York, New York + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Greenville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04402541" }, { "nct_id": "NCT02152956", "title": "Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AML" ], "interventions": [ { "name": "Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2014-06-09", "completion_date": "2022-07-05", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-10-15T05:54:29.485Z", "location_count": 20, "location_summary": "Duarte, California • La Jolla, California • San Francisco, California + 16 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02152956" }, { "nct_id": "NCT03557970", "title": "JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Edicotinib", "type": "DRUG" }, { "name": "Pharmacokinetic Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-10-05", "completion_date": "2020-09-28", "has_results": true, "last_update_posted_date": "2021-12-02", "last_synced_at": "2026-10-15T05:54:29.485Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03557970" }, { "nct_id": "NCT00322673", "title": "Study of XL999 in Patients With Acute Myeloid Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "AML" ], "interventions": [ { "name": "XL999", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphony Evolution, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2006-05", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2010-02-22", "last_synced_at": "2026-10-15T05:54:29.485Z", "location_count": 7, "location_summary": "Alhambra, California • Los Angeles, California • Northridge, California + 3 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Redondo Beach", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00322673" }, { "nct_id": "NCT00899951", "title": "Studying Fentanyl in Patients With Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Pain", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fentanyl citrate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2007-10", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2013-04-18", "last_synced_at": "2026-10-15T05:54:29.485Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899951" }, { "nct_id": "NCT00286845", "title": "Use of the MiCK Assay for Apoptosis in AML", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia, Myelocytic, Acute" ], "interventions": [ { "name": "Standard Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pierian Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2006-01", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2012-01-26", "last_synced_at": "2026-10-15T05:54:29.485Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00286845" }, { "nct_id": "NCT06969430", "title": "A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Debio 1562M", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2025-05-30", "completion_date": "2031-11", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-15T05:54:29.485Z", "location_count": 7, "location_summary": "Duarte, California • Tampa, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06969430" }, { "nct_id": "NCT00536601", "title": "High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Burkitt Lymphoma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Plasma Cell Neoplasm", "Primary Systemic Amyloidosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Neuroblastoma", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Regional Neuroblastoma", "Splenic Marginal Zone Lymphoma", "Testicular Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "etoposide", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "carmustine", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "autologous-autologous tandem hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 174, "start_date": "2006-06-29", "completion_date": "2018-07-09", "has_results": true, "last_update_posted_date": "2021-04-22", "last_synced_at": "2026-10-15T05:54:29.485Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00536601" }, { "nct_id": "NCT00427557", "title": "Cellular Therapy With Cord Blood Cells", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Leukemia", "Lymphoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Umbilical Cord Blood", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Infusion", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "80 Years", "sex": "ALL", "summary": "Up to 80 Years" }, "enrollment_count": 31, "start_date": "2006-10", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2012-05-28", "last_synced_at": "2026-10-15T05:54:29.485Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00427557" }, { "nct_id": "NCT03862157", "title": "Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Chronic Eosinophilic Leukemia, Not Otherwise Specified", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Essential Thrombocythemia", "Myelodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Myeloid Neoplasm", "Myeloproliferative Neoplasm", "Myeloproliferative Neoplasm, Unclassifiable", "Overt Primary Myelofibrosis", "Polycythemia Vera", "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase", "Prefibrotic/Early Primary Myelofibrosis" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2019-02-27", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-15T05:54:29.485Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03862157" } ] }